Rozek Elizabeth 4

What Happened

• Elizabeth Rozek, Chief Legal & Administrative Officer of Sagimet Biosciences (SGMT), received two equity awards on 2026-02-19: 44,000 restricted stock units (RSUs) and an 88,000-share derivative award (stock option/award). Both grants were recorded at $0.00 per share (no cash exchanged at grant).
• These are compensation awards (not open‑market purchases or sales) and therefore are routine equity compensation rather than an immediate buy or sell signal.

Key Details

• Transaction date: 2026-02-19; Form 4 filed 2026-02-20 (appears timely).
• Grant prices: $0.00 per share; aggregate value at grant shown as $0.
• Vesting:
  • RSUs (44,000) vest in four equal annual installments beginning Feb 19, 2026, subject to continued service (Footnote F1).
  • Derivative award (88,000) vests/becomes exercisable in 48 equal monthly installments beginning Feb 19, 2026, subject to continued service (Footnote F2).
• Shares owned after the transaction: not specified in the provided excerpt of the filing.
• No indication of tax withholding sales, 10b5-1 plan, or late filing in the provided details.

Context

• RSUs convert into shares only upon vesting and do not represent immediately tradable stock until settled. The 88,000‑share derivative award must vest and be exercised before resulting in owned shares.
• Grants are common executive compensation; they compensate and incentivize continued service rather than directly signal near‑term insider buying or selling.